Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. COO
COO logo

COO Overview

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Loading chart...

High
61.860
Open
60.830
VWAP
61.19
Vol
5.71M
Mkt Cap
11.94B
Low
60.500
Amount
349.69M
EV/EBITDA(TTM)
13.04
Total Shares
195.11M
EV
14.29B
EV/OCF(TTM)
16.49
P/S(TTM)
2.92
The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.
Show More

Events Timeline

(ET)
2026-05-04
17:10:00
Cooper Companies Appoints Paul Keel as Independent Director
select
2026-03-05 (ET)
2026-03-05
16:20:00
Sees FY26 Revenue of $4.306B-$4.346B
select

News

CNBC
2.0
05-29CNBC
Market Anticipates Resolution to Iran Conflict
  • Market Rebound: With growing confidence that the Strait of Hormuz will soon reopen, stocks are poised to end May at all-time highs, reflecting investor optimism about future economic recovery.
  • AI Driving Force: S&P 500 earnings are expected to grow over 28% in Q1, with the information technology sector seeing growth rates exceeding 54%, indicating that AI technology is driving profitability across industries and boosting market confidence.
  • Employment Market Outlook: Economists predict a 100,000 increase in May nonfarm payrolls, with the unemployment rate steady at 4.3%, suggesting that despite slowing job growth, the market is adapting to a
PRnewswire
5.0
05-29PRnewswire
CooperVision Appoints New President for Asia-Pacific Region
  • Leadership Appointment: CooperVision has appointed Muru Annamalai as President of Asia-Pacific effective June 1, 2026, leveraging his over 20 years of global leadership experience in the pharmaceutical and healthcare sectors to drive growth in this strategically important region.
  • Business Expansion Expertise: Annamalai's executive roles at AbbVie and Abbott have equipped him with the skills to expand operations in both emerging and established markets, delivering strong commercial results through collaborative leadership and strategic execution.
  • Deepening Customer Relationships: According to Chief Commercial Officer Debbie Olive, Annamalai's appointment is expected to accelerate growth, deepen customer partnerships, and expand access to CooperVision's portfolio across Asia-Pacific, further solidifying the company's market leadership.
  • Global Perspective: Originally from Malaysia, Annamalai holds a bachelor's degree in mathematics from the University Malaya and an MBA from Heriot-Watt University in the UK, bringing a global perspective shaped by decades of personal and professional experience that will contribute to CooperVision's strategic initiatives.
Newsfilter
5.0
05-29Newsfilter
CooperVision Appoints New President for Asia-Pacific Region
  • Leadership Change: CooperVision has appointed Muru Annamalai as President for Asia-Pacific effective June 1, 2026, reflecting the company's commitment to growth in this strategically important region.
  • Extensive Experience: Annamalai brings over 20 years of global leadership experience in the pharmaceutical and healthcare sectors, having held senior roles at AbbVie and Abbott, showcasing his exceptional capabilities in commercial organization and market expansion.
  • Strategic Goals: The new president's appointment aims to accelerate CooperVision's growth, deepen customer partnerships, and expand access to its portfolio across Asia-Pacific, further solidifying the company's leadership in the market.
  • Educational Background: Annamalai holds a bachelor's degree in mathematics from the University Malaya and an MBA from Heriot-Watt University in the UK, and his global perspective is expected to bring new strategic insights to CooperVision.
NASDAQ.COM
8.5
04-22NASDAQ.COM
Positive Outlook for Medical Supply Industry
  • Industry Growth Drivers: The global medical supplies market is projected to reach $163.5 billion by 2027, with a CAGR of 3.4%, indicating sustained growth driven by an aging population and innovation, benefiting companies like Cardinal Health and Becton, Dickinson.
  • Technological Innovations: The healthcare sector is transitioning to digital-first operating models with AI integration, where automation tools enhance efficiency and reduce administrative burdens, thereby supporting predictive care delivery and improving patient engagement.
  • Shifting Market Demand: The U.S. dental equipment market is structurally supported by demographic aging and rising disease prevalence, with the 65+ population driving increased procedure volumes and equipment utilization, reflecting a strong demand for high-quality healthcare services.
  • Competition and Challenges: Despite the optimistic outlook, the industry faces challenges from procurement pressures in China, inflation, and regulatory uncertainties, necessitating companies to diversify sourcing and optimize supply chains to maintain competitive positioning.
PRnewswire
8.5
04-09PRnewswire
CooperVision Launches Sustainability Platform to Enhance Eco-Friendly Practices
  • Sustainability Commitment: CooperVision's launch of the MADE BETTER™ Promise aims to reduce the carbon footprint of its MyDay® daily disposable contact lenses through smarter choices and sustainable manufacturing processes, enhancing brand image and meeting eco-conscious consumer demands.
  • Plastic Neutrality Program: The company has partnered with Plastic Bank to successfully recycle over 659 million plastic bottles, demonstrating its proactive contribution to reducing ocean plastic pollution while creating economic benefits for communities in participating countries.
  • Innovative Material Use: The MADE BETTER™ Innovation program incorporates ISCC PLUS-certified lower-carbon plastics and aluminum, which reduces packaging carbon emissions for MyDay® products, thereby enhancing their market competitiveness.
  • Production Efficiency Improvement: At its Puerto Rico manufacturing facility, the implementation of combined heat and power technology has reduced greenhouse gas emissions per lens by approximately 30% compared to 2021, not only improving production efficiency but also aligning with global environmental trends.
Globenewswire
5.0
04-08Globenewswire
Telix Pharmaceuticals Appoints New Non-Executive Directors
  • Board Expansion: Telix Pharmaceuticals announces the appointment of Maria Rivas and William Jellison as Non-Executive Directors effective May 11, 2026, aimed at enhancing governance and financial oversight to support the company's strategic development in the global biopharmaceutical sector.
  • Rivas's Background: Maria Rivas brings over 25 years of clinical development and commercialization experience, having served as Chief Medical Officer at Pfizer, where she oversaw the launch of multiple blockbuster medical products, and her expertise is expected to bolster Telix's capabilities in oncology and rare diseases.
  • Jellison's Experience: William Jellison has over 30 years of corporate finance leadership experience, including serving as CFO of Stryker Corporation, where he managed international finance and M&A, and his financial acumen will provide critical strategic support for Telix.
  • Strategic Implications: This board expansion aligns with Telix's evolution into a global commercial-stage biopharmaceutical company, reflecting the company's commitment to enhancing governance structures and increasing market competitiveness, which is expected to drive long-term growth in the biopharmaceutical industry.
Wall Street analysts forecast COO stock price to rise
12 Analyst Rating
Wall Street analysts forecast COO stock price to rise
7 Buy
4 Hold
1 Sell
Moderate Buy
Current: 0.000
sliders
Low
73.00
Averages
90.33
High
100.00
Current: 0.000
sliders
Low
73.00
Averages
90.33
High
100.00
Citi
Joanne Wuensch
Neutral
downgrade
$80 -> $69
AI Analysis
2026-05-28
New
Reason
Citi
Joanne Wuensch
Price Target
$80 -> $69
AI Analysis
2026-05-28
New
downgrade
Neutral
Reason
Citi analyst Joanne Wuensch lowered the firm's price target on Cooper Companies to $69 from $80 and keeps a Neutral rating on the shares.
Goldman Sachs
Sell
to
Sell
downgrade
$69 -> $61
2026-05-27
New
Reason
Goldman Sachs
Price Target
$69 -> $61
2026-05-27
New
downgrade
Sell
to
Sell
Reason
Goldman Sachs lowered the firm's price target on Cooper Companies to $61 from $69 and keeps a Sell rating on the shares. MedTech has experienced one of its weakest periods in 15-20 years across performance, valuation, and outlook revisions, pressured by sector rotation, slower growth, reimbursement and competitive risks, and aging investment narratives, the analyst tells investors in a research note.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for COO
Unlock Now

Valuation Metrics

The current forward P/E ratio for Cooper Companies Inc (COO.O) is 13.51, compared to its 5-year average forward P/E of 24.11. For a more detailed relative valuation and DCF analysis to assess Cooper Companies Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PE
24.11
Current PE
13.51
Overvalued PE
28.85
Undervalued PE
19.37

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average EV/EBITDA
17.91
Current EV/EBITDA
10.74
Overvalued EV/EBITDA
21.09
Undervalued EV/EBITDA
14.73

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
5Y Average PS
4.68
Current PS
2.61
Overvalued PS
5.72
Undervalued PS
3.64

Financials

AI Analysis
Annual
Quarterly

Whales Holding COO

K
Kovitz Investment Group Partners, LLC
Holding
COO
+15.08%
3M Return
W
Weiss Asset Management, LLC
Holding
COO
+9.52%
3M Return
T
Trajan Wealth, L.L.C.
Holding
COO
+8.15%
3M Return
T
Triodos Investment Management B.V.
Holding
COO
+8.00%
3M Return
S
Sustainable Growth Advisers, LP
Holding
COO
+6.15%
3M Return
M
Manning & Napier Advisors, LLC
Holding
COO
+5.77%
3M Return

Trading Trends

    Insider
    Hedge Fund
    Congress Trading

People Also Watch

Frequently Asked Questions

What is Cooper Companies Inc (COO) stock price today?

The current price of COO is 61.21 USD — it has increased 0.28

What is Cooper Companies Inc (COO)'s business?

The Cooper Companies, Inc. is a global medical device company. The Company operates in two business units: CooperVision and CooperSurgical. CooperVision segment is involved in the contact lens industry. CooperSurgical segment is involved in the fertility and women's health care market through its diversified portfolio of products and services, including fertility products and services, medical devices, cryostorage (such as cord blood and cord tissue storage) and contraception. CooperVision’s products include MyDay daily disposable, MyDay daily disposable toric, MyDay Energys, MyDay multifocal, Biofinity & Biofinity XR, Biofinity Energys. CooperSurgical’s portfolio includes INSORB, Lone Star, and the Doppler Blood Flow Monitor. It also offers a suite of single-use cordless surgical retractors with an integrated multi-light-emitting diode (LED) light source and dual smoke evacuation channels, and single-use surgical suction devices with an integrated, cordless radial LED light source.

What is the price predicton of COO Stock?

Wall Street analysts forecast COO stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for COO is90.33 USD with a low forecast of 73.00 USD and a high forecast of 100.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is Cooper Companies Inc (COO)'s revenue for the last quarter?

Cooper Companies Inc revenue for the last quarter amounts to 1.02B USD, increased 6.16

What is Cooper Companies Inc (COO)'s earnings per share (EPS) for the last quarter?

Cooper Companies Inc. EPS for the last quarter amounts to 0.66 USD, increased 26.92

How many employees does Cooper Companies Inc (COO). have?

Cooper Companies Inc (COO) has 15000 emplpoyees as of June 01 2026.

What is Cooper Companies Inc (COO) market cap?

Today COO has the market capitalization of 11.94B USD.